In all likelihood, the reality is somewhere in between. The true story of Netflix is not about the its dominance or implosion. Instead, Netflix's worth comes down to a rather pedestrian race between revenue growth and content cost inflation. Today, revenue growth is outpacing cost growth, but not by very much. To justify its sky-high valuation, Netflix will need to better leverage its existing content spending in the future.
A view from the bear side
Despite Netflix's strong rebound since the "Qwikster" fiasco in 2011, a surprisingly large number of investors think its business model is unsustainable. For example, TheStreet's Rocco Pendola has repeatedly argued that Netflix is all "smoke and mirrors." Pendola believes that big media companies such as Time Warner (TWX) and Disney (DIS) control the whole industry, and that Netflix can survive only as long as these competitors tolerate it.
Hot European Companies To Invest In Right Now: KAR Auction Services Inc (KAR)
KAR Auction Services, Inc., together with its subsidiaries, provides vehicle auction services in North America. It operates in three segments: ADESA Auctions, IAA, and AFC. The ADESA Auctions segment offers whole car auctions and related services to the vehicle remarketing industry through online auctions and auction facilities. This segment also provides value-added services, such as auction related, transportation, reconditioning, inspection, title and repossession administration and remarketing, and analytical services. The ADESA Auctions segment sells its products and services through commercial fleet operators, financial institutions, rental car companies, new and used vehicle dealers, and vehicle manufacturers and their captive finance companies to franchise and independent used vehicle dealers. The IAA segment offers salvage vehicle auctions and related services that facilitate the remarketing of damaged or low value vehicles designated as total losses by insurance companies and charity donation vehicles, as well as recovered stolen vehicles. This segment also provides inbound transportation, titling, salvage recovery, and claims settlement administrative services. The AFC segment offers floorplan financing, a short-term inventory-secured financing, to independent used vehicle dealers. As of December 31, 2012, the company had a network of 67 whole car auction and 163 salvage auction locations, as well as serviced auctions through 104 locations. The company was formerly known as KAR Holdings, Inc. and changed its name to KAR Auction Services, Inc. in November 2009. KAR Auction Services, Inc. was founded in 2006 and is headquartered in Carmel, Indiana.
Advisors' Opinion:- [By Marc Bastow]
Vehicle auction services company KAR (KAR) raised its quarterly dividend 31% to 25 cents per share, payable on Jan. 3 to shareholders of record as of Dec. 20.
KAR Dividend Yield: 3.53%
10 Best Managed Healthcare Stocks To Own Right Now: Sina Corporation(SINA)
SINA Corporation provides online media and mobile value-added services (MVAS) in the People?s Republic of China. It provides advertising, non-advertising, and free services through SINA.com, Weibo.com, and SINA Mobile. SINA.com offers free interest-based channels that provide region-focused format and content, including news, sports, automobile-related news, finance, entertainment, luxury, technology, digital, tools, collectibles, video, music, and wireless application protocol, as well as interactive platform for fashion-conscious users to share comments and ideas on a range of topics, such as health, cosmetics, and beauty. The company's microblogging platform, Weibo.com, enables its users to follow the hottest topics being discussed online, as well as discussions related to people they know. Weibo accounts consist of celebrities, commercial enterprises, government entities, and grass root Internet users. Its SINA Mobile service allows users to receive news and informatio n, download ring tones, mobile games and pictures, and participate in dating and friendship communities. The company also offers SINA Game, which serves as an interactive platform that provides users with downloads and gateway access to popular online games; SINA eReading, a shop for book reviews; SINA.net, an enterprise solutions platform to assist businesses and government bodies; and SINA Mall, an online shopping Website. In addition, it provides a platform for Chinese bloggers; photo-sharing platform; free email, VIP mail, and corporate email for enterprise users; audio and video-based instant messaging tools; proprietary search technology; and classified advertising services, as well as hosts topic-specific discussion forums in Chinese language; and creates user-maintained and supported online communities. The company has strategic cooperation agreement with China Unicom (Hong Kong) Limited. SINA Corporation was founded in 1997 and is headquartered in Shanghai, the Peop le?s Republic of China.
Advisors' Opinion:- [By Vera Yuan]
So far this year, our holdings in this area did not work well and the overall IT sector performance was dragged down especially by two small-cap companies��ina Corp (SINA) and Digital China Holdings. Sina, one of China�� most popular web portals, came under selling pressure due to market concerns that its Twitter-like online communications services Weibo, may be losing its growth momentum to a main competitor. However, we continue to hold Sina as we believe the target market for its competitor is different from Weibo and we also believe Sina�� current valuation does not reflect its other attractive underlying assets.From Matthews China Fund (Trades, Portfolio)�� Second Quarter 2014 Commentary.Also check out: Matthews China Fund Undervalued Stocks Matthews China Fund Top Growth Companies Matthews China Fund High Yield stocks, and Stocks that Matthews China Fund keeps buying Currently 0.00/512345
Rating: 0.0/5 (0 votes)
- [By Rick Munarriz]
Celebrities have a funny way of lifting a platform's visibility. Twitter was doing fine as a place for tech-forward folks to share short messages, but it really took off once entertainers took to pecking out 140-character missives. The same scenario played out in China with SINA's (NASDAQ: SINA ) Weibo. The moment top athletes, rockers, and movie stars took to Weibo, it became the undisputed micro-blog of choice for the world's most populous nation.
10 Best Managed Healthcare Stocks To Own Right Now: Catalyst Pharmaceutical Partners Inc.(CPRX)
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Advisors' Opinion:- [By Roberto Pedone]
Catalyst Pharmaceutical Partners (CPRX) is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock closed flat to $1.87 in Tuesday's trading session.
Tuesday's Range: $1.78-$1.98
52-Week Range: $0.41-$3.65
Tuesday's Volume: 1.62 million
Three-Month Average Volume: 2.20 millionFrom a technical perspective, CPRX closed off its intraday low of $1.78 to $1.87 with lighter-than-average volume. This stock has been uptrending for the last few weeks, with shares moving higher from its low of $1.29 to its recent high of $2.07. During that move, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CPRX within range of triggering a near-term breakout trade. That trade will hit if CPRX manages to take out some near-term overhead resistance levels at $2.07 to its 50-day moving average of $2.16 with high volume.
Traders should now look for long-biased trades in CPRX as long as it's trending above some near-term support at $1.63 and then once it sustains a move or close above those breakout levels with volume that's near or above 2.20 million shares. If that breakout hits soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.
If you take a look at the chart for Catalyst Pharmaceutical Partners, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.
Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.
Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Managed Healthcare Stocks To Own Right Now: Roche Holding AG (ROG.VX)
Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals are divided into two sub-divisions: Roche Pharmaceuticals and Chugai. It operates in the United States, Western Europe, Japan, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Asia-Pacific and Other regions. Diagnostics include five business areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan. Advisors' Opinion:- [By Lauren Pollock]
Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.
10 Best Managed Healthcare Stocks To Own Right Now: Pharma-Bio Serv Inc (PBSV.PK)
Pharma-Bio Serv, Inc.( Pharma-Bio), incorporated on June 8, 2006, is a compliance and technology transfer services consulting firm with a laboratory testing facility, servicing the Puerto Rico, United States and Europe markets. The Company is engaged in providing technical compliance consulting service, and microbiological and chemical laboratory testing services primarily to the pharmaceutical, chemical, medical device and biotechnology industries. The Company�� operating segments include Puerto Rico technical compliance consulting, United States technical compliance consulting, Ireland technical compliance consulting and a Puerto Rico microbiological and chemical laboratory testing division (Lab). These segments provide services primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets. As on April 30, 2012, the Company acquired 100% interest in its subsidiary, Pharma-IR.
The Company provides a broad range of compliance related consulting services. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It provides information technology consulting services and technical training/seminars. The Company offers services to its core industries already serviced as well as the cosmetic and food industries. The Company seeks opportunities in markets that could yield profitable margins using its professional consulting force and also provide services such as those performed by its microbiological testing laboratory facility, its information technology service division, Integratek, and its technical training division, Pharma Serv Academy.
The Company�� information technology services and consulting division based in Puerto Rico (Integratek) provides a variety of information technology services, such as Web pages and portals development, digital art design, intranets, extranets, software development including database integration, Window! s and Web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others.
Advisors' Opinion:- [By The Specialist]
Normally when one of my stocks reports its earnings results after hours on a Friday, I cringe in anticipation of a bad report. Normally Friday after hours is a time slot reserved for companies who have disappointing results to deliver and wish to stay off radar. Naturally, when I got the alert on a Friday afternoon that Pharma-Bio Serv (PBSV.PK) had just reported its earnings results, I had one eye shut when opening the press release, fearing what would be inside.
10 Best Managed Healthcare Stocks To Own Right Now: ArthroCare Corporation(ARTC)
ArthroCare Corporation, a medical device company, develops, manufactures, and markets surgical products primarily based on its minimally invasive patented Coblation technology in the Americas and internationally. The company?s Sports Medicine business provides energy-based systems and fixation technologies used to treat soft tissue injuries in the shoulders, knees, and hips. It offers ArthroWands product line that features Coblation based specialized disposable energy-based surgical wands designed for single patient use to treat orthopedic conditions, including shoulder, knee, hip, foot, ankle, elbow, and wrist injuries; and Soft-Tissue Fixation products comprising a line of specialized implants and instruments, such as knotless and traditional anchors for rotator cuff and labrum repairs in shoulder; screws for ligament reconstruction in knee; a range of arthroscopic suture passers; and reusable hand-held instruments, procedural kits, and accessories. The company?s Ear N ose and Throat (ENT) business provides surgical products used to treat conditions performed by ENT healthcare professionals. It offers various products for general head, neck, and oral surgical procedures, including sinus surgery, snoring treatment, nasal turbinates reduction, and adenoid and tonsil removal. The company also provides surgical products for the treatment of spine related and other conditions. Its products include SpineWand devices used to treat soft tissue conditions in spine; Plasma Disc Decompression products for treating contained herniated discs; Cavity SpineWand that reduces the size of malignant lesions in the vertebrae of patients suffering from spinal compression fractures; and WoundWand for acute and chronic wound debridement, and wound cleansing. ArthroCare sells its products to surgeons and specialized medical professionals through sales representatives, and independent sales agents and distributors. The company was founded in 1993 and is headquarte red in Austin, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Smith & Nephew PLC (NYSE: SNN) announced its plans to buy ArthroCare (NASDAQ: ARTC) for $1.7 billion in cash. Smith & Nephew will pay $48.25 per share in cash to acquire ArthroCare, representing a 6.3% premium to ArthroCare's closing price on January 31. - [By Jake L'Ecuyer]
Top Headline
Smith & Nephew PLC (NYSE: SNN) announced its plans to buy ArthroCare (NASDAQ: ARTC) for $1.7 billion in cash. Smith & Nephew will pay $48.25 per share in cash to acquire ArthroCare, representing a 6.3% premium to ArthroCare's closing price on January 31.
10 Best Managed Healthcare Stocks To Own Right Now: Ishares Msci Australia Inc (EWA)
iShares MSCI Australia Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Australian market, as measured by the MSCI Australia Index (the Index). The Index seeks to measure the performance of the Australian equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Chad Fraser]
Another option is to buy units of an Australian exchange traded fund (ETF) like the iShares MSCI Australia Index Fund (NYSE: EWA), one of the investments we cover in Australian Edge’s How They Rate universe, which keeps over 100 Australian companies and other investments under continuous review.
No comments:
Post a Comment